

bioMmune Technologies Inc.

Suite 300 – 576 Seymour Street

Vancouver, BC V6B 3K1

Tel: (604) 688-6775

Fax: (604) 688-6995

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Early Warning Report

June 5, 2013

**TSX Venture Exchange
Trading Symbol: IMU**

Vancouver, British Columbia – bioMmune Technologies Inc. (the “Company”), hereby announces that Mr. Rob Hutchison (the “Offeror”) has acquired direct ownership of 1,325,000 common shares of the Company and control and direction over an additional 1,325,000 common shares of the Company (collectively the “Shares”), representing collectively approximately 11.73% of the Company’s issued and outstanding common shares.

The Shares were acquired pursuant to the terms of the share exchange agreement dated for reference April 22, 2013 between the Company, bioMmune Advanced Technologies Inc. (formerly bioMmune Technologies Inc. and now a wholly-owned subsidiary of the Company) (“BAT”) and BAT shareholders (the “Shares Exchange Agreement”), whereby the Company acquired all of the issued and outstanding shares of BAT in exchange for common shares of the Company on a one-for-one basis, which transaction served as the Company’s Qualifying Transaction under the policies of the TSX Venture Exchange (the “TSXV”).

Further detailed disclosure is contained in the Company’s filing statement, which is available under the Company’s profile on SEDAR at www.sedar.com.

Prior to the completion of the Qualifying Transaction, the Offeror held 575,000 common shares and 175,000 incentive stock options of the Company, representing approximately 8.21% of the Company’s issued and outstanding common shares on a non-diluted basis. As a result of the foregoing acquisition, the Offeror owns a total of 1,900,000 common shares and 175,000 incentive stock options of the Company, and exercises control and direction over an aggregate 1,325,000 common shares of the Company, collectively representing 14.7% of the issued and outstanding common shares of the Company on a non-diluted basis. If the Offeror was to exercise all of his options, he would then hold 14.93% of the issued and outstanding common shares of the Company, assuming no other options, warrants or convertible securities of the Company are exercised or converted and no other shares are otherwise issued by the Company.

In connection with completion of the Company’s Qualifying Transaction, the Offeror entered into a Value Securities Escrow Agreement dated for reference May 22, 2013 among the Company, Computershare Investor Services Inc. and certain other security holders, pursuant to which 1,325,000 common shares owned by the Offeror are subject and 1,325,000 common shares over which the Offeror exercises control or direction are subject.

A report respective this acquisition will be filed with the British Columbia, Alberta and Ontario Securities Commission using SEDAR and will be available for viewing through the Internet at www.sedar.com.

On behalf of the Board of Directors

“Rob Hutchison”

Rob Hutchison
Executive Chairman

For further information please contact:

Rob Hutchison
Telephone: (604) 644-1232

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct. Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to the Company's stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect Company's intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Company's Filing Statement and initial public offering Prospectus for a more complete discussion of applicable risk factors and their potential effects, copies of which may be accessed through the Company's page on SEDAR at www.sedar.com. Given these risks and uncertainties, the reader is cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and the Company undertakes no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.